<DOC>
	<DOC>NCT00309478</DOC>
	<brief_summary>Primarily, this clinical investigation compared the efficacy of cyclophosphamide + methotrexate + fluorouracil chemotherapy vs. goserelin + tamoxifen treatment in terms of prognosis (disease-free survival, overall survival) in premenopausal patients with potentially curative, operated hormone receptor-positive breast cancer.</brief_summary>
	<brief_title>Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Premenopausal patients with histologically verified, lymph nodenegative (pT1cpT3) or lymph nodepositive (pT1apT3) breast cancer Hormone receptorpositive status More than 6 histologically examined lymph nodes Laboratory parameters 1. hematopoiesis: &gt; 3500/l leukocytes, &gt; 100,000/l thrombocytes 2. renal function: creatinin &lt; 1.5mg% 3. hepatic function: GOT &lt;/= 2.5 x UNL 4. bilirubin: &lt; 1.5mg % 5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar 6. blood coagulation: PZ &gt; 60% Concluded healing process following surgery &lt;/= 4 weeks interval since surgery Informed consent T4 carcinoma; inflammatory breast cancer, carcinoma in situ Simultaneous or sequential bilateral breast cancer Preoperative tumorreducing radiotherapy or preoperative tumorspecific medical treatment Male patients Pregnancy or lactation Lacking compliance or understanding of the disease General contraindication against cytostatic treatment Serious concomitant disease preventing implementation of adjuvant therapy or regular followup Second carcinoma or status post second carcinoma (except for curatively treated squamous cell carcinoma of the skin or cervical carcinoma in situ)</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Breast cancer</keyword>
</DOC>